-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $105

Benzinga·03/23/2026 11:06:08
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $100 to $105.